Updated:
Noso Capital
Somos una gestora de fondos de capital privado independiente que apuesta por proyectos empresariales de base tecnológica con impacto positivo en la...
Noso Capital
Somos una gestora de fondos de capital privado independiente que apuesta por proyectos empresariales de base tecnológica con impacto positivo en la sociedad
General information
Firm type
Private Equity
Year founded
—
AUM
Undisclosed
Location
Region
Europe
Country
Spain
City
Santiago de Compostela
Corporate office
Ed. Quercus IP, C/Letonia, 2 Esc. A-1º Local A, P.E. Costa Vella, 15707 Santiago de Compostela, A Coruña, Spain
Principals
Tomás Pérez
listed on team page
Vicente Espert
listed on team page
Sector focus
Frequently asked questions
How does Noso Capital source proprietary deal flow?
Noso sources primarily through its embedded position in the Galician innovation ecosystem. The firm organizes investor gatherings that draw more than 100 participants, and its Bio & Tech Smart Capital affiliate is homologated by CDTI as a coinvestor, which provides access to publicly vetted research-stage opportunities. This regional-public sourcing funnel is distinct from the broker-led processes common among generalist Iberian funds.
Is Noso Capital structured as a single family office or a traditional private equity firm?
Noso Capital is structured as an independent private equity manager, not a family office. It manages discretionary private capital and also operates Bio & Tech Smart Capital, a vehicle backed in part by NextGenerationEU funds and homologated by CDTI. This hybrid structure gives the firm two distinct deployment channels under one team.
Does Noso Capital participate in fund commitments or only direct deals?
Available evidence points to direct investment in startups at Seed and Series A-B stages. The firm’s website describes backing founders and executive teams with equity capital and management support; there is no public indication of fund-of-fund commitments or LP investments in third-party vehicles.
What investment stages does Noso Capital typically target?
Noso targets Seed and Series A-B rounds. The firm’s strategy spans early-stage venture through growth, with the portfolio concentrated in technology companies that have reached the point of commercial or clinical validation — examples include Pharmacelera’s €6 million raise for US expansion and ADNTRO Genetics’ professional-genetics rollout.
How is Noso Capital related to Bio & Tech Smart Capital?
Bio & Tech Smart Capital is an affiliated vehicle managed by the same team. It is homologated by CDTI as a coinvestor and receives NextGenerationEU backing, which effectively doubles the firm’s investment capacity when deploying through that vehicle. Noso uses the two entities in parallel, with Bio & Tech Smart Capital skewing toward public-private co-investment opportunities.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: